Balance Sheet
Accumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aimei Health Technology (AFJK) Liabilities and Shareholders Equity (2023 - 2025)

Aimei Health Technology (AFJK) has 3 years of Liabilities and Shareholders Equity data on record, last reported at $45.5 million in Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 37.53% to $45.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $207.4 million, a 27.58% decrease, with the full-year FY2024 number at $73.8 million, up 4.75% from a year prior.
  • Liabilities and Shareholders Equity reached $45.5 million in Q3 2025 per AFJK's latest filing, up from $44.6 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for AFJK hit a ceiling of $73.8 million in Q4 2024 and a floor of $43.6 million in Q1 2025.
  • A 3-year average of $61.7 million and a median of $70.9 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: increased 4.75% in 2024, then plummeted 38.83% in 2025.
  • Tracing AFJK's Liabilities and Shareholders Equity over 3 years: stood at $70.5 million in 2023, then rose by 4.75% to $73.8 million in 2024, then plummeted by 38.4% to $45.5 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for AFJK at $45.5 million in Q3 2025, $44.6 million in Q2 2025, and $43.6 million in Q1 2025.